The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
Open accessAbstract
BACKGROUND: The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative chemoradiotherapy. METHODS: In this phase 3, multicenter, randomized trial, we assigned in a 1:1 ratio patients with resectable esophageal adenocarcinoma to receive perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery. Eligibility criteria included a primary tumor with a clinical stage of cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease, in which T indicates the size and extent of the tumor (higher numbers indicate a more advanced tumor), and N indicates the presence (N+) or absence (N0) of cancer spread to the lymph nodes, without evidence of metastatic spread. The primary end point was overall survival. RESULTS: From February 2016 through April 2020, we assigned 221 patients to the FLOT group and 217 patients to the preoperative-chemoradiotherapy group. With a median follow-up of 55 months, overall survival at 3 years was 57.4% (95% confidence interval [CI], 50.1 to 64.0) in the FLOT group and 50.7% (95% CI, 43.5 to 57.5) in the preoperative-chemoradiotherapy group (hazard ratio for death, 0.70; 95% CI, 0.53 to 0.92; P = 0.01). Progression-free survival at 3 years was 51.6% (95% CI, 44.3 to 58.4) in the FLOT group and 35.0% (95% CI, 28.4 to 41.7) in the preoperative-chemoradiotherapy group (hazard ratio for disease progression or death, 0.66; 95% CI, 0.51 to 0.85). Among the patients who started the assigned treatment, grade 3 or higher adverse events were observed in 120 of 207 patients (58.0%) in the FLOT group and in 98 of 196 patients (50.0%) in the preoperative-chemoradiotherapy group. Serious adverse events were observed in 98 of 207 patients (47.3%) in the FLOT group and in 82 of 196 patients (41.8%) in the preoperative-chemoradiotherapy group. Mortality at 90 days after surgery was 3.1% in the FLOT group and 5.6% in the preoperative-chemoradiotherapy group. CONCLUSIONS: Perioperative chemotherapy with FLOT led to improved survival among patients with resectable esophageal adenocarcinoma as compared with preoperative chemoradiotherapy. (Funded by the German Research Foundation; ESOPEC ClinicalTrials.gov number, NCT02509286.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Al-Batran, S.-E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H.-G., Mayer, F., Haag, G. M., Luley, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32557-1 · Cited by 2,648
Self-citationYchou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.-M., Saint-Aubert, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0597 · Cited by 2,086
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827
Classification of adenocarcinoma of the oesophagogastric junction
Siewert, J. R., & Stein, H. J. (1998) · Journal of British Surgery · doi:10.1046/j.1365-2168.1998.00940.x · Cited by 1,267
Burmeister, B. H., Smithers, B. M., Gebski, V., Fitzgerald, L., Simes, R. J., Devitt, P., Ackland, S., Gotley, D. C., Joseph, D., Millar, J., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70288-6 · Cited by 926
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
Becker, K., Mueller, J. D., Schulmacher, C., Ott, K., Fink, U., Busch, R., Böttcher, K., Siewert, J. R., & Höfler, H. (2003) · Cancer · doi:10.1002/cncr.11660 · Cited by 827
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Obermannová, R., Alsina, M., Cervantes, A., Leong, T., Lordick, F., Nilsson, M., van Grieken, N. C. T., Vogel, A., & Smyth, E. C. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.003 · Cited by 730
Self-citation
Cited by
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Janjigian, Y. Y., Al-Batran, S.-E., Wainberg, Z. A., Muro, K., Molena, D., Van Cutsem, E., Hyung, W. J., Wyrwicz, L., Oh, D.-Y., Omori, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503701 · Cited by 333
Metadata
- Authors
- Hoeppner, J., Brunner, T., Schmoor, C., Bronsert, P., Kulemann, B., Claus, R., Utzolino, S., Izbicki, J. R., Gockel, I., Gerdes, B., Ghadimi, M., Reichert, B., Lock, J. F., Bruns, C., Reitsamer, E., Schmeding, M., Benedix, F., Keck, T., Folprecht, G., Thuss-Patience, P., Neumann, U. P., Pascher, A., Imhoff, D., Daum, S., Strieder, T., Krautz, C., Zimmermann, S., Werner, J., Mahlberg, R., Illerhaus, G., Grimminger, P., & Lordick, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-23
- Volume
- 392
- Issue
- 4
- Pages
- 323-335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4406717200
- Cited by
- 286
- References
- 14
- FWCI
- 249.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2409408
- The paper
- Hoeppner, J., Brunner, T., Schmoor, C., Bronsert, P., Kulemann, B., Claus, R., Utzolino, S., Izbicki, J. R., Gockel, I., Gerdes, B., Ghadimi, M., Reichert, B., Lock, J. F., Bruns, C., Reitsamer, E., Schmeding, M., Benedix, F., Keck, T., Folprecht, G., . . . Lordick, F. (2025). Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2409408
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.